用¹²⁵I标记的蛋白A结合试验检测慢性肝病患者血清中抗Chang肝细胞抗体以及泼尼松龙和6-巯基嘌呤治疗对抗体水平的影响。
Detection of antibodies to Chang liver cell in sera from patients with chronic liver diseases by 125I-labelled protein A binding assay and the effect of prednisolone and 6-mercaptopurine treatment on the level of the antibodies.
作者信息
Inagaki Y, Morizane T, Matsumura S, Kawamura N, Watanabe T, Kumagai N, Nakamura T, Tsuchimoto K, Tsuchiya M
出版信息
Clin Exp Immunol. 1984 Jul;57(1):79-84.
Antibody binding to living Chang liver cell was measured in sera from 71 patients with various chronic liver diseases using 125I-labelled protein A binding assay. The level of antibody binding to Chang liver cell was significantly elevated in sera from patients with chronic active hepatitis (CAH), chronic persistent hepatitis (CPH) and liver cirrhosis as compared to those from healthy donors, but not in sera from patients with fatty liver. There was no detectable antibody binding to HeLa cells in those sera. The antibody binding to Chang liver cell was blocked by a human liver specific protein (LSP) preparation. The levels of antibody binding to Chang liver cell were significantly higher in patients with CAH than patients with CPH. On the other hand, the level of antibody binding to Chang liver cell was significantly decreased in sera from patients with CAH after a treatment with prednisolone (PSL) for 2 months and a subsequent combined administration of 6MP and a maintenance dose of PSL for 1 month. These results suggest that antibodies to Chang liver cell are closely correlated with the activity of chronic liver disease and that PSL and 6MP treatment can reduce the level of the antibodies.
采用¹²⁵I标记蛋白A结合试验，检测了71例各种慢性肝病患者血清中抗体与活的张氏肝细胞的结合情况。与健康供者相比，慢性活动性肝炎（CAH）、慢性持续性肝炎（CPH）和肝硬化患者血清中与张氏肝细胞结合的抗体水平显著升高，但脂肪肝患者血清中未升高。在这些血清中未检测到与HeLa细胞结合的抗体。与张氏肝细胞结合的抗体被一种人肝特异性蛋白（LSP）制剂阻断。CAH患者血清中与张氏肝细胞结合的抗体水平显著高于CPH患者。另一方面，CAH患者血清在用泼尼松龙（PSL）治疗2个月，随后联合应用6-巯基嘌呤（6MP）和维持剂量的PSL治疗1个月后，与张氏肝细胞结合的抗体水平显著降低。这些结果表明，抗张氏肝细胞抗体与慢性肝病的活动密切相关，PSL和6MP治疗可降低抗体水平。
Zotero 插件